Update 2018: 18F-FDG PET/CT and PET/MRI in Head and Neck Cancer

Yasemin Sanli, Katherine Zukotynski, Erik Mittra, Delphine L. Chen, Helen Nadel, Ryan D. Niederkohr, Rathan Subramaniam

Research output: Contribution to journalArticle

2 Scopus citations


There are recent advances, namely, a standardized method for reporting therapy response (Hopkins criteria), a multicenter prospective cohort study with excellent negative predictive value of 18F-FDG PET/CT for N0 clinical neck, a phase III multicenter randomized controlled study establishing the value of a negative posttherapy 18F-FDG PET/CT for patient management, a phase II randomized controlled study demonstrating radiation dose reduction strategies for human papilloma virus-related disease, and Food and Drug Administration approval of nivolumab for treatment of recurrent head and neck squamous cell carcinoma.

Original languageEnglish (US)
Pages (from-to)E439-E452
JournalClinical Nuclear Medicine
Issue number12
StatePublished - Dec 1 2018


  • head and neck cancer
  • PET/CT
  • PET/MR

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'Update 2018: 18F-FDG PET/CT and PET/MRI in Head and Neck Cancer'. Together they form a unique fingerprint.

  • Cite this

    Sanli, Y., Zukotynski, K., Mittra, E., Chen, D. L., Nadel, H., Niederkohr, R. D., & Subramaniam, R. (2018). Update 2018: 18F-FDG PET/CT and PET/MRI in Head and Neck Cancer. Clinical Nuclear Medicine, 43(12), E439-E452. https://doi.org/10.1097/RLU.0000000000002247